Article
Emergency Medicine
Joshua Lucas, Abhijith Bathini, Karen Greenberg
Summary: Acute myeloid leukemia (AML) is a common type of leukemia in children, with a better prognosis compared to older populations. This case study highlights an atypical presentation of AML with diplopia as the initial symptom, emphasizing the importance of thorough evaluation for patients with unexplained diplopia.
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2021)
Letter
Oncology
Xin Jin, Meng Zhang, Rui Sun, Hairong Lyu, Xia Xiao, Xiaomei Zhang, Fan Li, Danni Xie, Xia Xiong, Jiaxi Wang, Wenyi Lu, Hongkai Zhang, Mingfeng Zhao
Summary: This study evaluates the efficacy and safety of CLL-1 CAR-T cell therapy in adults with R/R AML. All patients developed cytokine release syndrome (CRS), but none developed CAR-T cell-related encephalopathy syndrome (CRES). Despite severe pancytopenia in all patients, a 70% complete response (CR) or CR with incomplete hematologic recovery (CRi) rate was achieved.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Na An, Yuming Pan, Linlin Yang, Qiongli Zhang, Sisi Deng, Qiaoxia Zhang, Xin Du
Summary: We found that CD38-CAR-T cells were effective against AML, and downregulation of PI3Kd in CD38-CAR-T cells reduced cytokine release without impairing their anti-leukemia function. The study demonstrated the promising activity of CD38-CAR-T cells against AML and the potential to enhance their efficacy through PI3Kd downregulation.
MOLECULAR PHARMACEUTICS
(2023)
Article
Immunology
Ling Tang, Yingjie Kong, Haobing Wang, Ping Zou, Ting Sun, Ying Liu, Juan Zhang, Na Jin, Hanwen Mao, Xiaojian Zhu, Jue Wang, Fankai Meng, Yong You
Summary: CD44v6 CAR-T cells show strong anti-tumor ability and safety in AML, but their expression of CD44v6 leads to transient fratricide and exhaustion. DNA methylation affects T cell exhaustion and CD44v6 expression in AML cells. Dec and Aza enhance the function of CD44v6 CAR-T cells and promote apoptosis in AML cells, making them a promising combination therapy for AML patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Matthias Boehme, Sabine Kayser
Summary: This review provides a summary of various immune-based approaches for the treatment of acute myeloid leukemia (AML), including immune checkpoint inhibitors, bispecific T-cell engager antibodies, and chimeric antigen receptor-T-cell (CAR-T) therapies. The development and design of these immune-based strategies have become increasingly important in AML, based on successful immunotherapies in solid cancers. The review covers a wide range of approaches, from antibody drug conjugates to T-cell-based therapies, and discusses ongoing clinical trials and their potential contributions to understanding AML pathogenesis and finding the most effective immunotherapeutic strategies.
Review
Biochemistry & Molecular Biology
Rikako Tabata, SungGi Chi, Junichiro Yuda, Yosuke Minami
Summary: Studies have suggested the potential clinical benefits of immuno-oncology therapy against AML, including immune checkpoint inhibitors and bi-/tri-specific antibodies. CAR-T and NK cells have shown effectiveness for relapsed/refractory AML patients, and conventional chemotherapy combined with anti-PD-1/anti-CTLA4 antibodies also demonstrated certain efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Hematology
Tim Sauer, Kathan Parikh, Sandhya Sharma, Bilal Omer, David Sedloev, Qian Chen, Linus Angenendt, Christoph Schliemann, Michael Schmitt, Carsten Mueller-Tidow, Stephen Gottschalk, Cliona M. Rooney
Summary: CD70 is a promising target antigen for AML treatment, and CD70-CAR T cells demonstrate good proliferation and antitumor activity in vitro and in vivo for CD70-positive AML patients, showing potential as a new treatment strategy.
Article
Oncology
Noa G. Holtzman, Michael S. Lebowitz, Rima Koka, Maria R. Baer, Kanam Malhotra, Amir Shahlaee, Hossein A. Ghanbari, Soren M. Bentzen, Ashkan Emadi
Summary: ASPH is expressed on blasts in approximately 40% of AML cases, and may serve as a new therapeutically targetable leukemia-associated antigen.
FRONTIERS IN ONCOLOGY
(2021)
Review
Immunology
Christopher Schorr, Fabiana Perna
Summary: Acute Myeloid Leukemia (AML) is an aggressive malignancy with limited therapeutic options. CAR T-cell therapy for AML faces challenges due to lack of target antigens, clonal heterogeneity, and immunosuppressive bone marrow. This study provides an updated overview of AML targets and clinical trials with CAR T-cells, serving as a potential guide for adoptive cellular therapies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Mayumi Sugita, Roman Galetto, Hongliang Zong, Nathan Ewing-Crystal, Vicenta Trujillo-Alonso, Nuria Mencia-Trinchant, Winnie Yip, Stephanie Filipe, Celine Lebuhotel, Agnes Gouble, Duane C. Hassane, Julianne Smith, Gail J. Roboz, Monica L. Guzman
Summary: This study reports the design and characterization of allogeneic CD123-targeted CAR-T cells as a therapeutic approach for acute myeloid leukemia.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Yang Xiao, Jinghong Chen, Jia Wang, Wei Guan, Mengzhen Wang, Linlin Zhang, Zhiding Wang, Lixin Wang, Li Yu
Summary: In patients with AML, the expression of ICAM-1 is silenced, but the hypomethylating agent can upregulate its expression, facilitating NK cells to kill AML cells. High expression of ICAM-1 can reverse AML immune evasion and activate NK cell function, suggesting a new strategy for AML treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Anatomy & Morphology
Evgeniy S. Seliverstov
Summary: Examining changes in the surface of immature reticulocytes using atomic force microscopy can provide important prognostic value in studying bone marrow activity during acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Editorial Material
Cell & Tissue Engineering
Malini Gupta, Britta Will
Summary: Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this study, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as a targeted opportunity for mitigating malignant cell growth in AML.
Article
Biochemistry & Molecular Biology
Rafaela G. A. Costa, Suellen L. R. Silva, Ingrid R. S. B. Dias, Maiara de S. Oliveira, Ana Carolina B. da C. Rodrigues, Rosane B. Dias, Daniel P. Bezerra
Summary: Acute myeloid leukemia (AML) is a heterogeneous disease group with various mutations triggering malignant proliferation. AML relapse is mainly caused by leukemic stem cells (LSCs) with self-renewal capacity and resistance to traditional therapies. LSCs have low oxidative stress levels due to low mitochondrial activity and high ROS-removing pathway activity. Targeting oxidative stress could be a potential strategy to eliminate AML LSCs.
Article
Multidisciplinary Sciences
Wei-Yu Lin, Sarah E. Fordham, Eric Hungate, Nicola J. Sunter, Claire Elstob, Yaobo Xu, Catherine Park, Anne Quante, Konstantin Strauch, Christian Gieger, Andrew Skol, Thahira Rahman, Lara Sucheston-Campbell, Junke Wang, Theresa Hahn, Alyssa I. Clay-Gilmour, Gail L. Jones, Helen J. Marr, Graham H. Jackson, Tobias Menne, Mathew Collin, Adam Ivey, Robert K. Hills, Alan K. Burnett, Nigel H. Russell, Jude Fitzgibbon, Richard A. Larson, Michelle M. Le Beau, Wendy Stock, Olaf Heidenreich, Abrar Alharbi, David J. Allsup, Richard S. Houlston, Jean Norden, Anne M. Dickinson, Elisabeth Douglas, Clare Lendrem, Ann K. Daly, Louise Palm, Kim Piechocki, Sally Jeffries, Martin Bornhauser, Christoph Rollig, Heidi Altmann, Leo Ruhnke, Desiree Kunadt, Lisa Wagenfuhr, Heather J. Cordell, Rebecca Darlay, Mette K. Andersen, Maria C. Fontana, Giovanni Martinelli, Giovani Marconi, Miguel A. Sanz, Jose Cervera, Ines Gomez-Segui, Thomas Cluzeau, Chimene Moreilhon, Sophie Raynaud, Heinz Sill, Maria Teresa Voso, Francesco Lo-Coco, Herve Dombret, Meyling Cheok, Claude Preudhomme, Rosemary E. Gale, David Linch, Julia Gaal-Wesinger, Andras Masszi, Daniel Nowak, Wolf-Karsten Hofmann, Amanda Gilkes, Kimmo Porkka, Jelena D. Milosevic Feenstra, Robert Kralovics, David Grimwade, Manja Meggendorfer, Torsten Haferlach, Szilvia Krizsan, Csaba Bodor, Friedrich Stolzel, Kenan Onel, James M. Allan
Summary: The study conducted a genome-wide association analysis on European patients with AML, identifying genetic loci associated with the risk of developing the disease. The results shed light on potential functional genes involved in histone methylation and immune function in AML etiology.
NATURE COMMUNICATIONS
(2021)
Article
Genetics & Heredity
Sarra Bchir, Hela ben Nasr, Imen Rekik Hakim, Amel ben Anes, Saloua Yacoub, Abdelhamid Garrouch, Mohamed Benzarti, Brigitte Bauvois, Zouhair Tabka, Karim Chahed
MOLECULAR DIAGNOSIS & THERAPY
(2015)
Article
Oncology
Sandrine Bouchet, Ruoping Tang, Fanny Fava, Ollivier Legrand, Brigitte Bauvois
Article
Cell Biology
Sarra Bchir, Hela ben Nasr, Sandrine Bouchet, Mohamed Benzarti, Abdelhamid Garrouch, Zouhair Tabka, Santos Susin, Karim Chahed, Brigitte Bauvois
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2017)
Article
Endocrinology & Metabolism
Yuejun Liu, Judith Aron-Wisnewsky, Genevieve Marcelin, Laurent Genser, Gilles Le Naour, Adriana Torcivia, Brigitte Bauvois, Sandrine Bouchet, Veronique Pelloux, Magali Sasso, Veronique Miette, Joan Tordjman, Karine Clement
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2016)
Editorial Material
Cell Biology
Brigitte Bauvois
JOURNAL OF LEUKOCYTE BIOLOGY
(2014)
Article
Oncology
Sandrine Bouchet, Ruoping Tang, Fanny Fava, Ollivier Legrand, Brigitte Bauvois
Review
Oncology
Sandrine Bouchet, Brigitte Bauvois
Review
Oncology
Brigitte Bauvois, Santos A. Susin
Article
Oncology
Brigitte Bauvois, Elodie Pramil, Ludovic Jondreville, Elise Chapiro, Claire Quiney, Karim Maloum, Santos A. Susin, Florence Nguyen-Khac
Article
Biochemistry & Molecular Biology
Brigitte Bauvois, Elodie Pramil, Ludovic Jondreville, Claire Quiney, Florence Nguyen-Khac, Santos A. Susin
Summary: The study reveals that both type I and II interferons promote survival of chronic lymphocytic leukemia cells by activating the STAT3/Mcl-1 signaling pathway, inhibiting intrinsic apoptosis. Inhibitors against STAT3, TYK2 (for type I IFN), JAK2 (for type II IFN), and Src family kinase PP2 can effectively reduce interferon-mediated cell survival. Combining conventional treatments with inhibitors targeting STAT3 and Mcl-1 may offer a new therapeutic strategy for CLL.
Review
Oncology
Emile Verhulst, Delphine Garnier, Ingrid De Meester, Brigitte Bauvois
Summary: Cell surface proteases, known as ectoproteases, play a role in cancer development and targeting them with inhibitors shows potential for improving cancer treatment outcomes. Despite limited efficacy in some cases, efforts in developing ectoprotease inhibitors are expanding with the goal of discovering novel therapeutic strategies for cancer treatment.
Article
Food Science & Technology
Abdelkarim Ben Arfa, Mondher Boulaaba, Faten Merhi, Brigitte Bauvois, Arnault Ingrid, Jacques Auger, Mohamed Neffati, Hanen Najjaa
Summary: Epidemiological studies support the proposition that Allium vegetables can lower the risk of cancer. This study found that extracts from Allium roseum inhibit the growth of acute leukemia cells without inducing apoptosis, while promoting cell differentiation.
FOOD SCIENCE & NUTRITION
(2023)
Review
Oncology
Kenza Dubois, Mariana Tannoury, Brigitte Bauvois, Santos A. Susin, Delphine Garnier
Summary: Chronic lymphocytic leukemia (CLL) is a type of cancer characterized by the accumulation of abnormal B lymphocytes in the immune system. Despite the development of new therapies, drug resistance and disease relapse still occur. The interactions between leukemic B cells and the microenvironment play a crucial role in treatment resistance. Extracellular vesicles released into the microenvironment have emerged as key players in this cross-talk and can potentially be targeted for novel therapeutics.
Article
Critical Care Medicine
Fouad Fadel, Gwennan Andre-Gregoire, Basile Gravez, Brigitte Bauvois, Sandrine Bouchet, Catalina Sierra-Ramos, Andrea Polito, Arnaud Mansart, Diego Alvarez de la Rosa, Djillali Annane, Frederic Jaisser
CRITICAL CARE MEDICINE
(2017)
Article
Biochemistry & Molecular Biology
Sandrine Bouchet, Marion Piedfer, Santos Susin, Daniel Dauzonne, Brigitte Bauvois
AIMS MOLECULAR SCIENCE
(2016)
Article
Pharmacology & Pharmacy
Paola Orlandi, Marta Banchi, Francesca Vaglini, Marco Carli, Stefano Aringhieri, Arianna Bandini, Carla Pardini, Cristina Viaggi, Michele Lai, Greta Ali, Alessandra Ottani, Eleonora Vandini, Patrizia Guidi, Margherita Bernardeschi, Veronica La Rocca, Giulio Francia, Gabriella Fontanini, Mauro Pistello, Giada Frenzilli, Daniela Giuliani, Marco Scarselli, Guido Bocci
Summary: This study investigates the role of MC4R in melanoma and the use of the selective antagonist ML in combination with vemurafenib. The results show that ML can inhibit melanoma cell proliferation and induce apoptosis through the inhibition of ERK1/2 phosphorylation and reduction of BCL-XL expression. The combination of vemurafenib and ML exhibits a synergistic effect in vitro and inhibits tumor growth in vivo without causing adverse effects.
BIOCHEMICAL PHARMACOLOGY
(2024)
Article
Pharmacology & Pharmacy
Conor J. Bloxham, Katina D. Hulme, Fabrizio Fierro, Christian Fercher, Cassandra L. Pegg, Shannon L. O'Brien, Simon R. Foster, Kirsty R. Short, Sebastian G. B. Furness, Melissa E. Reichelt, Masha Y. Niv, Walter G. Thomas
Summary: Bitter taste receptors (T2Rs) are a type of G protein-coupled receptors that allow humans to detect aversive and toxic substances. This study characterized the functional properties of previously identified T2Rs in human cardiac tissues and their naturally occurring polymorphisms. The results showed differences in signaling among different T2R variants, and revealed a potential association between the T2R50 Tyr203 variant and cardiovascular disease.
BIOCHEMICAL PHARMACOLOGY
(2024)
Article
Pharmacology & Pharmacy
Lu Chen, Huanying Shi, Wenxin Zhang, Yongjun Zhu, Haifei Chen, Zimei Wu, Huijie Qi, Jiafeng Liu, Mingkang Zhong, Xiaojin Shi, Tianxiao Wang, Qunyi Li
Summary: This study demonstrates that Carfilzomib exhibits potent anti-tumor activity against esophageal squamous cell carcinoma (ESCC) by triggering mitochondrial apoptosis and reprogramming cellular metabolism. It has been identified that activating transcription factor 3 (ATF3) plays a crucial role as a cellular target in ESCC cells treated with Carfilzomib. Overexpression of ATF3 effectively counteracts the effects of Carfilzomib on ESCC cell proliferation, apoptosis, and metabolic reprogramming. Furthermore, ATF3 mediates the anti-tumor activity of Carfilzomib, suggesting its potential as a therapeutic agent for ESCC.
BIOCHEMICAL PHARMACOLOGY
(2024)
Review
Pharmacology & Pharmacy
Xing Zhang, Xiang Li, Ran Xia, Hong-Sheng Zhang
Summary: This review summarizes recent progress on the mechanisms of ferroptosis resistance in cancer and highlights the role of redox status and metabolism. Combination therapy for ferroptosis has great potential in treating resistant malignant tumors.
BIOCHEMICAL PHARMACOLOGY
(2024)